MétaCan
Menu
Back to cohort
Record W4226041390 · doi:10.1158/1055-9965.epi-21-0600

The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource

2022· article· en· W4226041390 on OpenAlexafffund
Véronique Ouellet, Andrew Erickson, Kathy E. Wiley, Colm Morrissey, Viktor Berge, Carlos S. Moreno, Kristin Austlid Taskén, Dominique Trudel, Lawrence D. True, Michael Lewis, Aud Svindland, Onur Ertunç, Igor Vidal, Adeboye O. Osunkoya, Tracy Jones, G. Steven Bova, Tarja Lamminen, Ariel H. Achtman, Mark Buzza, Michelle M. Kouspou, Steven A. Bigler, Xinchun Zhou, Stephen J. Freedland, Anne‐Marie Mes‐Masson, Isla P. Garraway, Bruce J. Trock, Pekka Taimen, Fred Saad, Tuomas Mirtti, Beatrice S. Knudsen, Angelo M. De Marzo

Bibliographic record

VenueCancer Epidemiology Biomarkers & Prevention · 2022
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsUniversité de MontréalCentre Hospitalier de l’Université de Montréal
FundersFonds de Recherche du Québec - SantéSidney Kimmel Comprehensive Cancer CenterNational Cancer InstituteNational Institutes of HealthDOD Prostate Cancer Research ProgramInstitute for Prostate Cancer ResearchMovember FoundationJohns Hopkins UniversityU.S. Department of Defense
KeywordsProstate cancerProstatectomyMedicineTissue microarrayProstateOncologyMetastasisBiomarkerDiseaseCancerCancer researchInternal medicineBiology

Abstract

fetched live from OpenAlex

BACKGROUND: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations. METHODS: Three separate TMA sets were built that differ by purpose and disease state. RESULTS: The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases. CONCLUSIONS: The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation. IMPACT: This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.023
Threshold uncertainty score0.078

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.009
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.003
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0020.003
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0230.011

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.075
GPT teacher head0.421
Teacher spread0.346 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueCancer Epidemiology Biomarkers & PreventionSame topicProstate Cancer Treatment and ResearchFrench-language works237,207